Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections [3]

Research output: Contribution to journalLetterpeer-review

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)236-237
Number of pages2
JournalClinical Infectious Diseases
Issue number2
StatePublished - Jan 15 2003

Bibliographical note

Funding Information:
A randomized trial comparing vanco mycin, linezolid, and TMP-SMZ in the treatment of MRSA infections would be most timely. However, given the probable absence of an interested corporate sponsor, support for such a trial may be needed from nonprofit and governmental entities concerned with health care costs and antimicrobial resistance, including the National Institutes of Health, the Centers for Disease Control and Prevention, the US Food and Drug Administration, the IDSA, and the US Department of Veterans Affairs.

Cite this